Evidence map›Paper›PMID 40229246›Full record

ArticleNature communications2025

Drugit: crowd-sourcing molecular design of non-peptidic VHL binders.

Thomas Scott, Christian Alan Paul Smethurst, Yvonne Westermaier, Moriz Mayer, Peter Greb, Roland Kousek, Tobias Biberger, Gerd Bader, Zuzana Jandova, Philipp S Schmalhorst and 16 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2.Journal of chemical information and modeling · 2026
    Article
  2. CACHE Challenge #2: Targeting the RNA Site of the SARS-CoV-2 Helicase Nsp13.Journal of chemical information and modeling · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Thomas Scott *Department of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.
Christian Alan Paul Smethurst *Boehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.
Yvonne WestermaierBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0002-0462-8650
Moriz MayerBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.
Peter GrebBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0002-6757-4370
Roland KousekBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.
Tobias BibergerBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.
Gerd BaderBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0002-8410-3415
Zuzana JandovaBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.
Philipp S SchmalhorstBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0002-5795-0133
Julian E FuchsBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0003-4322-9481
Aniket MagarkarBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.ORCID http://orcid.org/0000-0003-3385-964X
Christoph HoenkeBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.
Thomas GerstbergerBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0002-6837-1401
Steven A CombsDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.
Richard PapeDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.
Saksham PhulDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.ORCID http://orcid.org/0000-0002-2771-2572
Sandeepkumar KothiwaleDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.
Andreas BergnerBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.
Foldit Players
Alex G WatersonDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.
Harald WeinstablBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0003-1308-2730
Darryl B McConnellBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.ORCID http://orcid.org/0000-0002-2537-3458
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA. jens@meilerlab.org.ORCID http://orcid.org/0000-0001-8945-193X
Jark BöttcherBoehringer Ingelheim RCV, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria. jark.boettcher@boehringer-ingelheim.com.ORCID http://orcid.org/0000-0003-2189-5926
Rocco MorettiDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA. rocco.moretti@vanderbilt.edu.ORCID http://orcid.org/0000-0003-2162-1116

Funding

GPU-Accelerated Parallel Computer for Life Sciences ResearchS10OD032234 · OD · VANDERBILT UNIVERSITY · PI SMITH, JARROD ANSON · 2022 to 2022
$600k
Parallel Computer with High Memory NodesS10OD016216 · OD · VANDERBILT UNIVERSITY · PI PISTON, DAVID W · 2013 to 2013
$598k
GPU-Accelerated Parallel Computer for Drug Discovery ApplicationsS10OD020154 · OD · VANDERBILT UNIVERSITY · PI SMITH, JARROD ANSON · 2015 to 2015
$225k
NIH HHS S10 OD016216NIH HHS S10 OD020154NIH HHS S10 OD032234
6 · The paper itself

Abstract

Building on the role of human intuition in small molecule drug design, we explored whether crowdsourcing could recruit citizen scientists to this task while in parallel building awareness for this scientific process. Here, we introduce Drugit ( https://drugit.org ), the small molecule design mode of the online citizen science game Foldit. We demonstrate its utility by identifying distinct binders to the von Hippel Lindau E3 ligase. Several thousand molecules were suggested by players in a series of ten puzzle rounds. The proposed molecules were further evaluated in silico and manually by an expert panel. Selected candidates were synthesized and tested. One of these molecules shows dose-dependent shift perturbations in protein-observed NMR experiments. The co-crystal structure in complex with the E3 ligase reveals that the observed binding mode matches the player's original idea. The completion of one full design cycle is a proof of concept for the Drugit approach and highlights the potential of involving citizen scientists in early drug discovery.

Indexed as

CrowdsourcingDrug DesignSmall Molecule LibrariesVon Hippel-Lindau Tumor Suppressor ProteinCrystallography, X-RayDrug DiscoveryHumansModels, MolecularProtein BindingSmall Molecule LibrariesVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID40229246
PMCPMC11997059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.